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Background: Papillary thyroid cancer (PTC) often presents as multifocal. However, the association of multifocality
with poor prognosis remains controversial. The aim of this retrospective study was to identify the characteristics of
PTC with multiple foci and to evaluate the association between multifocality and prognosis.
Methods: We reviewed the medical records of 496 patients who underwent total thyroidectomy for PTC. Patients
were classified as G1 (1 tumor focus), G2 (2 foci), and G3 (3 or more foci). We analyzed the clinicopathological
features and clinical outcomes in each classification. A Cox regression model was used to assess the relationship
between multifocality and recurrence or cancer mortality.
Results: The G1, G2 and G3 groups included 287, 141 and 68 patients, respectively. The mean age was 47.1 ±
16.1 yr in G1, 41.1 ± 18.4 yr in G2, and 35.5 ± 15.9 yr in G3 and differed significantly among the 3 groups (p = 0.001).
The proportion of extrathyroidal extension, central lymph node metastasis (CLNM), and lateral lymph node
metastasis (LLNM) in the G1 to G3 groups increased with increasing number of tumor foci. The Kaplan–Meier
curves revealed that G3 had the shortest recurrence-free survival, and differences were significant among the 3
groups (p = 0.001, Log Rank test). Furthermore, cancer-specific survival rates decreased significantly with increasing
number of tumor foci (p = 0.041). Independent predictors of recurrence by multivariate Cox analysis included >3
tumor foci [HR 2.60, 95% confidence interval (CI) 1.53-4.39, p = 0.001] and extrathyroidal extension (HR 1.95,
CI 1.12-3.38, p = 0.018).
Conclusion: An increase in the number of tumors is associated with a tendency toward more aggressive features
and predicts poor prognosis in PTC.
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The number of newly diagnosed thyroid carcinoma cases
is increasing annually, and an estimated 62,980 cases will
be diagnosed in the United States in 2014, more than
90% of which will be papillary thyroid cancer (PTC)
[1,2]. PTC often presents as multifocal tumors [3], which
are thought to arise independently, indicating an inher-
ent propensity to develop PTC, and spread throughout
the thyroid gland [4].
PTC is generally an indolent disease and has a favorable
prognosis in most affected patients; however, PTC with
multifocal foci is likely to be aggressive and, accordingly,* Correspondence: jiqinghai@shca.org.cn
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unless otherwise stated.require aggressive treatment [5,6]. The characteristics of
PTC with multifocal foci and the prognostic significance
of multifocality in PTC remain controversial [7,8]. We
performed a retrospective analysis to examine the charac-
teristics of multifocal PTC and the relationship between
the number of tumor foci and PTC prognosis in a large
group of Chinese patients with long-term follow-up.Methods
Patients
The records of all PTC patients treated at our center
between January 1, 1983, and December 31, 2007, were
retrospectively reviewed. All patients provided written
informed consent for their information to be stored in the
hospital database and used for research, and this study
was approved by the Ethical Committee of the Cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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PTC patients who underwent primary surgical therapy of
total thyroidectomy (TT) were enrolled in this study,
representing 23.5% of the total 2115 patients treated at
our center during the corresponding period.
Initial treatment
Before surgery, each patient underwent an ultrasonog-
raphy (US) examination. US-guided fine-needle aspir-
ation (FNA) was not performed routinely. Lobectomy
plus ipsilateral central lymph node dissection (CLND)
was typically performed as the initial surgical treatment
for PTC patients with malignant lesions that were lim-
ited to a single lobe [9]. When the patient was older
than 45 yr, the primary tumor was greater than 1 cm,
undetermined nodules were detected in the contralateral
lobe by US or regional metastases or multifocal tumors
were present, TT was performed at the time of the initial
operation. When undetermined nodules were detected
in the contralateral lobe by US without other factors, a
subtotal lobectomy of approximately one-fourth to two-
thirds of the contralateral lobe was performed on the
suspicion of lesions in the contralateral lobe following
the preoperative US. Histology of the frozen sections
(FS) assisted surgeons in determining the extent of the
surgical procedures. When malignant lesions were iden-
tified in both lobes of the thyroid by FS after a subtotal
lobectomy, a completion thyroidectomy (CT) was per-
formed [9]. Modified lateral lymph node dissection
(LLND), including levels II–V, was performed in cases
with pathologically proven lymph node metastasis (LNM)
or suspicious lymph nodes observed intraoperatively or on
preoperative imaging.
Suppressive treatment with thyroid hormone was initi-
ated after surgery to decrease serum thyroid-stimulating
hormone (TSH) to subnormal levels without clinical
thyrotoxicosis. Because its use is strictly controlled in
China, radioactive iodine (RAI) therapy was not routinely
prescribed for PTC patients after surgery unless patients
had distant metastases [9].
Clinicopathological variable assessment and
statistical analysis
Multifocality was defined as 2 or more tumor foci within
the thyroid. For multifocal tumors, the diameter of the
largest tumor focus was taken as the primary tumor. In
addition, data on patient clinical features (gender, age at
diagnosis), tumor histological characteristics (maximum
size of tumor, extrathyroidal extension), and cervical LNM
were extracted from the database.
Follow-up
All patients gave consent to participate in the follow-up
study. The follow-up period for each patient was definedas the length of time from the initial therapy until the
last known date of contact documented by a review of
the medical record or as a follow-up phone call to the
patient. Postsurgical physical examinations were per-
formed every 3–6 months. During the follow-up visits, all
patients underwent US examinations of the neck. Recur-
rence was defined as the appearance of disease, including
new biopsy-proven/secondary surgery-confirmed local dis-
ease or distant disease revealed by ultrasonography and/or
imaging scans, in any patient who had been free of disease
(i.e., no palpable disease and negative radioactive iodine
scan). New biopsy-proven/secondary surgery-confirmed
local disease within the residual thyroid gland or lateral
lymph nodes was classified as neck recurrence; distant dis-
ease revealed by ultrasonography and/or imaging scans of
other sites, including the lungs, bones or brain, was classi-
fied as distant recurrence.
Statistical analysis
The results are expressed as the mean ± standard deviation.
Statistical analysis was performed using Student’s t test, Χ2
test or Mann–Whitney test as appropriate. Patients who
were alive and who did not relapse were censored at
the date of their last follow-up visit. Neck/metastasis
recurrence-free survival (RFS) was defined as the time
between the date of initial surgery and the first event
of recurrence or death. Overall survival (OS) was de-
fined as the time between the date of initial surgery and
death (all causes or cancer-specific). Cancer-specific sur-
vival (CSS) was defined as the time between the date of
initial surgery and cancer-specific death. Survival rates were
estimated using the Kaplan-Meier method [10]. The hazard
ratio (HR) and the 95% confidence interval (CI) for rela-
tionships between each variable and recurrence were calcu-
lated using a binary Cox regression model [11]. A p < 0.05
was considered statistically significant. Statistical analyses
were performed using SPSS for Windows 13.0 (SPSS Inc.,
Chicago, IL).Results
Baseline characteristics of patients
At the time of diagnosis, the 496 patients ranged in age
from 7 to 85 yr (mean 43.8 ± 17.3 yr). The series com-
prised 336 females (67.7%) and 160 males (32.3%), with
a female/male ratio of 2.1/1. Based on postoperative
pathology, the mean maximal tumor size was 2.31 ±
1.59 cm. Multifocality was observed in 209 patients
(42.1%). Extrathyroidal extension was evident in 207
cases (41.7%). A total of 381 patients (76.8%) exhibited
central lymph node metastasis (CLNM), and 306 pa-
tients (61.7%) exhibited lateral lymph node metastasis
(LLNM). No patients had a history of familial PTC. The
characteristics of the patients are presented in Table 1.
Table 1 Clinicopathological characteristics of 496
papillary thyroid cancer patients
Variables Number (%)
Male gender 160 (32.3)
Age 43.8 ± 17.3 yr
Maximum size of tumor (cm) 2.31 ± 1.59
Multifocality 209 (42.1)
Number of tumor foci 1.2 ± 1.3
Extrathyroidal extension 207 (41.7)
Central lymph node metastasis 381 (76.8)
Lateral lymph node metastasis 306 (61.7)
Data are presented as n (%) or mean ± standard deviation.
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tumor foci
Based on the number of tumor foci, the population was
divided into 3 groups: G1 (1 tumor focus), G2 (2 foci),
and G3 (3 or more foci). Patients with a solitary tumor
(n = 287, 57.9%) were classified as G1. Patients with
multifocal tumors were classified as G2 (n = 141, 28.4%)
or G3 (n = 68, 13.7%). Table 2 presents the characteris-
tics of patients according to the number of tumor foci.
The mean age was 47.1 ± 16.1 yr in G1, 41.1 ± 18.4 yr
in G2, and 35.5 ± 15.9 yr in G3 and differed significantly
among the 3 groups (p = 0.001). A decreasing trend of
age was observed from G1 to G3 according to the in-
creasing number of tumor foci.
The incidence of neck recurrence was highest in group
G3, followed by group G2 and group G1, and differedTable 2 Clinicopathological features of papillary thyroid








Male gender 94 (32.8) 43 (30.5) 23 (33.8) NS
Age 47.1 ± 16.1 yr 41.1 ± 18.4 yr 35.5 ± 15.9 yr <0.05
Maximum size
of tumor (cm)
2.29 ± 1.41 2.35 ± 1.9 2.37 ± 1.60 NS
Extrathyroidal
extension
115 (40.1) 60 (42.6) 32 (47.1) NS
Central lymph
node metastasis
215 (74.9) 110 (78.0) 56 (82.4) NS
Lateral lymph
node metastasis
173 (60.3) 80 (56.7) 53 (77.9) NS
Neck recurrence 19 (6.6) 24 (17.6) 14 (20.6) <0.05
Distant recurrence 8 (2.8) 7 (5.0) 7 (10.3) NS
Died of thyroid
cancer
4 (1.4) 6 (6.4) 5 (7.4) NS
Data are presented as n (%) or mean ± standard deviation.
Abbreviations: G1 1 tumor focus, G2 2 tumor foci, G3 3 or more tumor foci,
NS not significant.
Age at diagnosis and primary tumor size were compared using the
Kruskal-Wallis test.
Group comparisons of categorical variables were performed using the chi-square
test or, for small cell values, Fisher’s exact test.significantly among the 3 groups (p = 0.037). However,
there were no significant differences with respect to gender,
maximum tumor size, extrathyroidal extension, CLNM,
LLNM, distant recurrence or cancer-specific death among
the 3 groups. However, the proportion of aggressive
features, such as extrathyroidal extension, CLNM, and
LLNM, in the G1 to G3 groups exhibited an increasing
trend according to the number of tumor foci.
Number of tumor foci and recurrence
The mean length of follow-up was 124.3 ± 67.8 months,
with a range of 10 to 343 months. During the follow-up
period, 57 patients (11.5%) experienced neck recur-
rence, including recurrence in the thyroid or operation
bed (n = 13), lateral neck (n = 40), or both locations (n = 4).
Distant recurrences occurred in 22 patients (4.4%), includ-
ing 16 lung metastases, 5 bone metastases, and 1 brain
metastasis. Four patients exhibited both neck recurrence
and distant recurrence; therefore, the frequency of total
recurrence was 15.1% (75/496), and the RFS rate was
84.3% at 10 yr, 70.8% at 15 yr, and 69.6% at 20 yr from the
time of the initial operation. The Kaplan–Meier curve was
used to investigate the differences in RFS rates among the
3 groups (Figure 1). Patients with 3 or more tumor foci ex-
hibited the shortest RFS, followed by G1 and G2, and dif-
ferences were significant among the 3 groups (p = 0.001,
Log Rank test).
To determine how strongly the number of tumor foci
was associated with recurrence relative to other known
predictors of recurrence in PTC, we performed multi-
variate Cox regression analysis. Instead of limiting the
multivariate analysis to the significant terms from the
univariate analysis, we included all variables because
these factors have been previously demonstrated to be
important in predicting disease recurrence in adult PTC
patients. The results are presented in Table 3. The risk of
recurrence increased with increasing number of tumor
foci, and G3 exhibited a greater risk of recurrence thanFigure 1 Kaplan-Meier curves for recurrence-free survival (RFS)
in the G1, G2 and G3 groups. (Log Rank test, p = 0.001).
Table 3 Multivariate cox regression for recurrence
Independent variable Multivariate analysis
HR (95% CI) p value
Gender (female vs. male) 0.65 (0.41-1.03) 0.063
Age 1.00 (0.99-1.02) 0.872
Size 1.12 (0.98-1.28) 0.108
Extrathyroidal extension 1.95 (1.12 -3.38) 0.018
Number of tumor foci
G1 (1 tumor focus) 1 (reference)
G2 (2 foci) 2.06 (1.05-4.01) 0.034
G3 (3 or more foci) 2.60 (1.53-4.39) 0.001
Central lymph node metastasis 0.65 (0.33-1.25) 0.194
Lateral lymph node metastasis 1.07 (0.52-2.16) 0.862
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addition, extrathyroidal extension was an independent
predictor of recurrence (HR 1.95, 95% CI 1.12 -3.38,
p = 0.018).Number of tumor foci and survival
Deaths were observed in 45 patients; however, cancer-
specific deaths only occurred in 15 patients. OS and CSS
were 92.4% and 96.9% at 10 yr, 86.7% and 94.6% at 15 yr,
and 78.6% and 89.1% at 20 yr from the initial operation,
respectively. The Kaplan–Meier curve was used to inves-
tigate the differences in CSS rates among the 3 groups
(Figure 2). The G3 group exhibited the lowest rate of
CSS; thus, PTC patients with 3 or more tumor foci had
the greatest risk of recurrence, followed by group G2
and group G1. Although a trend of decreasing CSS with
increasing number of tumor foci was observed, the dif-
ferences in CSS were not significant among the 3 groups
(p = 0.087, Log Rank test).Figure 2 Kaplan-Meier curves for cancer-specific survival (CSS)
in the G1, G2 and G3 groups. (Log Rank test, p = 0.087).Complications
Of the 496 patients, 26 (5.2%) had transient hypopara-
thyroidism, and 6 (1.2%) had permanent hypoparathyr-
oidism. Recurrent laryngeal nerve injury occurred in 11
patients (2.2%), of which 2 were transient (0.4%) and 9
were permanent (1.8%).
Discussion
In this study, we investigated the relationship between
the number of tumor foci and other clinicopathological
features and the impact of multifocality on prognosis in
PTC. We observed that an increasing number of tumor
foci was associated with both a tendency toward more
aggressive features as well as poor prognosis in PTC.
Few studies have addressed the associations between
the number of tumor foci and clinicopathological fea-
tures in multifocal PTCs. Kim et al. [12] reported that
an increase in the number of tumor foci was strongly as-
sociated with older age at diagnosis, cervical LNM, and
advanced TNM stage of PTC; furthermore, the number
of tumor foci independently predicted LNM. In accord-
ance with their findings, we observed that an increasing
number of tumor foci was associated with a tendency
toward more aggressive features, such as larger primary
tumor size, more frequent extrathyroidal extension and
cervical LNM. Although these differences were too small
to be significant, they suggest that multifocality might
represent the tumor burden and predict more aggressive
behavior during disease progression. An interesting finding
of the current study was that an increasing number of
tumor foci was associated with a younger age at diagnosis
in PTC, in contrast to previous reports that advanced age is
a prognostic factor for poor prognosis in PTC [12-15].
Younger age may indicate greater risk for the evolution of
biological aggressiveness, such as multifocality; we previ-
ously reported that younger age is significantly associated
with cervical LNM in PTC. However, appropriate initial
management may improve the prognosis of younger PTC
patients. Younger age as a predictor of multifocality empha-
sizes the need for more aggressive therapy to achieve the
relatively preferable outcomes observed in elderly patients.
Recent studies of the relationship between multifocality
and oncological outcomes have suggested that multifocal
lesions in PTC are positively associated with poorer prog-
nosis in patients. Kim et al. [16] reviewed the medical re-
cords of 2095 patients who underwent total thyroidectomy
for PTC and reported that multifocality is associated with
an increased risk of disease recurrence and persistence,
suggesting that the number of tumor foci is a significant
predictor of poor clinical outcomes. We determined that
multifocality is a risk factor for poor outcomes; further-
more, we observed that a higher number of tumors had a
strong linear effect on the risk of recurrence (Table 2 and
Figure 1) and was also associated with a trend toward a
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CSS rates did not differ significantly among the 3 groups
(Figure 2). In addition, the predictive impact of tumor
numbers on recurrence was persistent in multivariate Cox
regression analysis when all variables were included
(Table 3). Thus, a higher number of tumors, particularly
≥3 tumor foci, is an independent predictor of disease re-
currence and a possible indicator of cancer death in PTC.
Extrathyroidal extension was another predictor for recur-
rence, consistent with previous studies [17-19]. However,
some studies of the prognostic impact of tumor multifocal-
ity in papillary thyroid microcarcinoma (PTMC) have
suggested that multifocal lesions do not appear to have
prognostic impact in PTMC [20]. Given the high incidence
of multifocality in PTMC, 20-40% [21-23], further studies
of small PTC tumors are needed to investigate the true role
and influence of multifocality in this subtype of PTC.
At our center, TT was not routinely performed in PTC
as an initial treatment. Considering the high incidence and
negative influence of multifocality, extensive TT surgery is
more likely to remove all disease foci and improve prog-
nosis, particularly in PTC patients with ≥3 tumor foci and
extrathyroidal extension. In addition, the rates of compli-
cations for permanent hypoparathyroidism and recurrent
laryngeal nerve injury were both within the ranges of 0-4%
and 0-6% reported in previous studies [24,25], suggesting
that thyroidectomy plus lymph node dissections can be
performed safely and with low morbidity by experts.
Our study has several limitations that must be taken
into account. First, since this study was a retrospective
analysis, the prognostic significance of tumor foci has
not been fully investigated. The long-term follow-up
studies are needed to confirm the prognostic significance
in PTC. Second, our study population was a cohort of
patients cared for in a single center. Therefore, a much
larger number of subjects in multicenter will be needed
to generalize this results. At last, the fact that patients in
China only receive radioiodine for distant metastases
may significantly alter the outcome of patients in other
countries where radioiodine is given, but this study cer-
tainly shows the impact of significant sized multifocality
when radioiodine is not given.
Conclusion
We observed that a higher number of PTC foci was asso-
ciated with a tendency toward more aggressive features,
including greater primary tumor size, more frequent
extrathyroidal extension and cervical LNM. In addition,
an increase in the number of tumors was associated with
an increased risk of recurrence and a trend toward more
cancer mortality. Our findings suggested that the number
of tumor foci could be used to assess the risk of poor
prognosis, and TT is recommended in patients with more
tumor foci.Abbreviations
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